These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

661 related items for PubMed ID: 20025693

  • 21. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA, Wolf A, O'shea D, Erny S, Ruof J.
    Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
    [Abstract] [Full Text] [Related]

  • 23. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY, Thomas GN, Chan JC, Tomlinson B.
    Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
    [Abstract] [Full Text] [Related]

  • 24. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ, Wilton LV, Shakir SA.
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [Abstract] [Full Text] [Related]

  • 25. Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials.
    Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM.
    Int J Obes (Lond); 2005 May; 29(5):509-16. PubMed ID: 15685250
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials.
    Czernichow S, Lee CM, Barzi F, Greenfield JR, Baur LA, Chalmers J, Woodward M, Huxley RR.
    Obes Rev; 2010 Feb; 11(2):150-8. PubMed ID: 19573052
    [Abstract] [Full Text] [Related]

  • 27. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 28. Long-term pharmacotherapy for obesity.
    Klein S.
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [Abstract] [Full Text] [Related]

  • 29. Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis.
    Reinhart KM, Coleman CI, Teevan C, Vachhani P, White CM.
    Ann Pharmacother; 2008 Dec; 42(12):1766-71. PubMed ID: 19017826
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW.
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [Abstract] [Full Text] [Related]

  • 31. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N, Ryan DH, Renz CL, Hewkin AC.
    Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
    [Abstract] [Full Text] [Related]

  • 32. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.
    Padwal R, Li SK, Lau DC.
    Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1437-46. PubMed ID: 12975638
    [Abstract] [Full Text] [Related]

  • 33. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
    Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS.
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):207-10. PubMed ID: 17570651
    [Abstract] [Full Text] [Related]

  • 34. Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.
    Hemo B, Endevelt R, Porath A, Stampfer MJ, Shai I.
    Diabetes Res Clin Pract; 2011 Nov; 94(2):269-75. PubMed ID: 21907442
    [Abstract] [Full Text] [Related]

  • 35. Orlistat.
    Wong NN, Cheng-Lai A.
    Heart Dis; 2000 Nov; 2(2):174-81. PubMed ID: 11728255
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C, Semlitsch T.
    Cochrane Database Syst Rev; 2021 Jan 17; 1(1):CD007654. PubMed ID: 33454957
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
    Viner RM, Hsia Y, Tomsic T, Wong IC.
    Obes Rev; 2010 Aug 17; 11(8):593-602. PubMed ID: 19922432
    [Abstract] [Full Text] [Related]

  • 39. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E, Martín Folgueras T.
    Nutr Hosp; 2011 Aug 17; 26(3):451-7. PubMed ID: 21892560
    [Abstract] [Full Text] [Related]

  • 40. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis.
    Neovius M, Johansson K, Rössner S.
    Obes Rev; 2008 Sep 17; 9(5):420-7. PubMed ID: 18208467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.